Advice

following an abbreviated submission:

zanamivir (Dectova®) is accepted for use within NHSScotland.

Indication under review: For the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥ 6 months) when:

  • the patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or
  • other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.

Zanamivir should be used in accordance with official guidance.

Unlicensed intravenous zanamivir was previously available in a compassionate use programme. A licensed medicine is now available.

Download detailed advice379KB (PDF)

Download

Medicine details

Medicine name:
zanamivir (Dectova)
SMC ID:
SMC2204
Indication:

Treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥ 6 months) when: • The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or • Other anti-viral agents for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.

Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Submission type
Abbreviated
Status
Accepted
Date advice published:
09 December 2019